Literature DB >> 25833397

CD28 Promotes Plasma Cell Survival, Sustained Antibody Responses, and BLIMP-1 Upregulation through Its Distal PYAP Proline Motif.

Cheryl H Rozanski1, Adam Utley1, Louise M Carlson1, Matthew R Farren1, Megan Murray1, Lisa M Russell2, Jayakumar R Nair1, ZhengYu Yang3, William Brady3, Lee Ann Garrett-Sinha2, Stephen P Schoenberger4, Jonathan M Green5, Lawrence H Boise6, Kelvin P Lee7.   

Abstract

In health, long-lived plasma cells (LLPC) are essential for durable protective humoral immunity, and, conversely, in disease are a major source of pathogenic Abs in autoimmunity, graft rejection, and allergy. However, the molecular basis for their longevity is largely unknown. We have recently found that CD28 signaling in plasma cells (PC) is essential for sustaining Ab titers, by supporting the survival of LLPC, but not short-lived PC (SLPC). We now find that, unlike SLPC, CD28 activation in LLPC induces prosurvival downstream Vav signaling. Knockin mice with CD28 cytoplasmic tail mutations that abrogate Vav signaling (CD28-AYAA) had significantly fewer LLPC but unaffected SLPC numbers, whereas mice with mutations that abrogate PI3K signaling (CD28-Y170F) were indistinguishable from wild-type controls. This was consistent with the loss of CD28's prosurvival effect in LLPC from CD28-AYAA, but not CD28-Y170F, mice. Furthermore, the CD28 Vav motif in the B lineage was essential for the long-term maintenance of Ag-specific LLPC populations and Ab titers in vivo. Signaling downstream of the CD28 Vav motif induced previously undescribed transcriptional regulation of B lymphocyte-induced maturation protein-1, a key mediator of PC differentiation and maintenance. These findings suggest CD28 signaling in LLPC modulates the central B lymphocyte-induced maturation protein-1 transcriptional nexus involved in long-term survival and function.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25833397      PMCID: PMC4416738          DOI: 10.4049/jimmunol.1402260

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

Review 1.  Regulation of plasma-cell development.

Authors:  Miriam Shapiro-Shelef; Kathryn Calame
Journal:  Nat Rev Immunol       Date:  2005-03       Impact factor: 53.106

Review 2.  SLP76 and SLP65: complex regulation of signalling in lymphocytes and beyond.

Authors:  Gary A Koretzky; Farhad Abtahian; Michael A Silverman
Journal:  Nat Rev Immunol       Date:  2006-01       Impact factor: 53.106

Review 3.  Long-lived plasma cells: a mechanism for maintaining persistent antibody production.

Authors:  M K Slifka; R Ahmed
Journal:  Curr Opin Immunol       Date:  1998-06       Impact factor: 7.486

4.  Malignant plasma cell lines express a functional CD28 molecule.

Authors:  X G Zhang; D Olive; J Devos; C Rebouissou; M Ghiotto-Ragueneau; M Ferlin; B Klein
Journal:  Leukemia       Date:  1998-04       Impact factor: 11.528

5.  Humoral immunity due to long-lived plasma cells.

Authors:  M K Slifka; R Antia; J K Whitmire; R Ahmed
Journal:  Immunity       Date:  1998-03       Impact factor: 31.745

6.  Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4.

Authors:  J H Horspool; P J Perrin; J B Woodcock; J H Cox; C L King; C H June; D M Harlan; D C St Louis; K P Lee
Journal:  J Immunol       Date:  1998-03-15       Impact factor: 5.422

7.  B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation.

Authors:  F Borriello; M P Sethna; S D Boyd; A N Schweitzer; E A Tivol; D Jacoby; T B Strom; E M Simpson; G J Freeman; A H Sharpe
Journal:  Immunity       Date:  1997-03       Impact factor: 31.745

8.  CD28, a marker associated with tumoral expansion in multiple myeloma.

Authors:  N Robillard; G Jego; C Pellat-Deceunynck; D Pineau; D Puthier; M P Mellerin; S Barillé; M J Rapp; J L Harousseau; M Amiot; R Bataille
Journal:  Clin Cancer Res       Date:  1998-06       Impact factor: 12.531

9.  Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells.

Authors:  Miriam Shapiro-Shelef; Kuo-I Lin; Louise J McHeyzer-Williams; Jerry Liao; Michael G McHeyzer-Williams; Kathryn Calame
Journal:  Immunity       Date:  2003-10       Impact factor: 31.745

10.  Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow.

Authors:  Miriam Shapiro-Shelef; Kuo-I Lin; David Savitsky; Jerry Liao; Kathryn Calame
Journal:  J Exp Med       Date:  2005-11-28       Impact factor: 14.307

View more
  26 in total

1.  The Histone Demethylase LSD1 Regulates B Cell Proliferation and Plasmablast Differentiation.

Authors:  Robert R Haines; Benjamin G Barwick; Christopher D Scharer; Parimal Majumder; Troy D Randall; Jeremy M Boss
Journal:  J Immunol       Date:  2018-09-19       Impact factor: 5.422

2.  Delayed Cytotoxic T Lymphocyte-Associated Protein 4-Immunoglobulin Treatment Reverses Ongoing Alloantibody Responses and Rescues Allografts From Acute Rejection.

Authors:  J S Young; J Chen; M L Miller; V Vu; C Tian; J J Moon; M-L Alegre; R Sciammas; A S Chong
Journal:  Am J Transplant       Date:  2016-04-04       Impact factor: 8.086

3.  CD86 regulates myeloma cell survival.

Authors:  Catherine M Gavile; Benjamin G Barwick; Scott Newman; Paola Neri; Ajay K Nooka; Sagar Lonial; Kelvin P Lee; Lawrence H Boise
Journal:  Blood Adv       Date:  2017-11-16

4.  Control of Humoral Response in Renal Transplantation by Belatacept Depends on a Direct Effect on B Cells and Impaired T Follicular Helper-B Cell Crosstalk.

Authors:  Claire Leibler; Allan Thiolat; Carole Hénique; Chloé Samson; Caroline Pilon; Marie Tamagne; France Pirenne; Benoit Vingert; José L Cohen; Philippe Grimbert
Journal:  J Am Soc Nephrol       Date:  2018-01-10       Impact factor: 10.121

5.  From Pipe Dream to Donor-Specific PC Elimination: Novel Ways to Target Alloantibodies.

Authors:  Anita S Chong
Journal:  Transplantation       Date:  2016-11       Impact factor: 4.939

6.  The impact of belatacept on third-party HLA alloantibodies in highly sensitized kidney transplant recipients.

Authors:  Ronald F Parsons; Arslan Zahid; Shalini Bumb; Hannah Decker; Harold C Sullivan; Frances Eun-Hyung Lee; Idelberto Raul Badell; Mandy L Ford; Christian P Larsen; Thomas C Pearson; Annette M Jackson; Dong-Feng Chen; Matthew Levine; Malek Kamoun; Robert A Bray; Howard M Gebel
Journal:  Am J Transplant       Date:  2019-10-08       Impact factor: 8.086

7.  Belatacept and CD28 Costimulation Blockade: Preventingand Reducing Alloantibodies over the Long Term.

Authors:  Ronald F Parsons; Christian P Larsen; Thomas C Pearson; I Raul Badell
Journal:  Curr Transplant Rep       Date:  2019-11-02

Review 8.  New insights into the development of B cell responses: Implications for solid organ transplantation.

Authors:  Anita S Chong
Journal:  Hum Immunol       Date:  2018-09-18       Impact factor: 2.850

9.  Dual targeting: Combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients.

Authors:  Christopher K Burghuber; Miriam Manook; Brian Ezekian; Adriana C Gibby; Frank V Leopardi; Minqing Song; Jennifer Jenks; Frances Saccoccio; Sallie Permar; Alton B Farris; Neal N Iwakoshi; Jean Kwun; Stuart J Knechtle
Journal:  Am J Transplant       Date:  2018-09-17       Impact factor: 8.086

10.  Differentiation stage of myeloma plasma cells: biological and clinical significance.

Authors:  B Paiva; N Puig; M T Cedena; B G de Jong; Y Ruiz; I Rapado; J Martinez-Lopez; L Cordon; D Alignani; J A Delgado; M C van Zelm; J J M Van Dongen; M Pascual; X Agirre; F Prosper; J I Martín-Subero; M-B Vidriales; N C Gutierrez; M T Hernandez; A Oriol; M A Echeveste; Y Gonzalez; S K Johnson; J Epstein; B Barlogie; G J Morgan; A Orfao; J Blade; M V Mateos; J J Lahuerta; J F San-Miguel
Journal:  Leukemia       Date:  2016-08-01       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.